• Publications
  • Influence
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur have beenExpand
  • 1,092
  • 120
  • PDF
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
  • E. Shane, D. Burr, +24 authors M. Whyte
  • Medicine, Biology
  • Journal of bone and mineral research : the…
  • 1 November 2010
Reports linking long‐term use of bisphosphonates (BPs) with atypical fractures of the femur led the leadership of the American Society for Bone and Mineral Research (ASBMR) to appoint a task force toExpand
  • 902
  • 77
  • PDF
Clinician’s Guide to Prevention and Treatment of Osteoporosis
The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council ofExpand
  • 1,673
  • 61
  • PDF
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
BACKGROUND A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annualExpand
  • 818
  • 57
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
BACKGROUND Small increases in bone mass are commonly seen with existing treatments for osteoporosis, which reduce bone remodelling and primarily prevent bone loss. Since these drugs reduce but do notExpand
  • 682
  • 52
Clinician’s Guide to Prevention and Treatment of Osteoporosis
The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council ofExpand
  • 478
  • 50
Anabolic actions of parathyroid hormone on bone.
I. Introduction PHYSICIANS have traditionally considered PTH to be an agent that is catabolic to the skeleton. However, as early as 60 yr ago, Albright and his colleagues (1) and later Selye (2)Expand
  • 673
  • 44
Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study *
We examined paired iliac crest bone biopsy specimens from patients with osteoporosis before and after treatment with daily injections of 400 U of recombinant, human parathyroid hormone 1–34Expand
  • 579
  • 44
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
BACKGROUND Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. METHODS We enrolled 7180 postmenopausal women who had a T score of -2.5Expand
  • 483
  • 31
  • PDF
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
Osteoporosis in men poses a unique therapeutic challenge. Clinical studies have focused largely on the more prevalent problem of post-menopausal osteoporosis, with few gender-specific studiesExpand
  • 370
  • 22